<DOC>
	<DOCNO>NCT00222612</DOCNO>
	<brief_summary>A randomised trial child acute lymphoblastic leukemia , use detection minimal residual disease define risk group , aim answer question : 1 . Can treatment reduce without compromise efficacy MRD-defined low risk group ? 2 . Does post-remission intensification improve outcome MRD-defined high risk group ? 3 . Measure Quality Life impact different treatment arm child family .</brief_summary>
	<brief_title>Medical Research Council ( MRC ) Working Party Leukaemia Children UK National Acute Lymphoblastic Leukaemia ( ALL ) Trial : UKALL 2003</brief_title>
	<detailed_description>Randomisations Patients assign MRD risk group base day 29 post consolidation MRD result randomise follow : 1 . MRD Low Risk Group ( MRD negative day 29 week 11 positive &lt; 1 x 10-4 day 28 negative week 11 ) continue previously assign Regimens ( A B ) randomise two delayed intensification one delay intensification . 2 . MRD High Risk Group ( MRD positive &gt; 1 x 10-4 day 29 ) randomise previously assign Regimen ( A B ) Regimen C. 3 . MRD Indeterminate Group ( No MRD result MRD positive &lt; 1 x 10-4 day 29 week 11 ) continue previously assign Regimen ( A B ) receive two delayed intensification</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Inclusion criterion : Children age 1 18 year ALL except follow : Exclusion criterion : 1 . Infants less year old enter onto Interfant ALL study . 2 . Children BALL ( Burkittlike , ( 8 ; 14 ) , L3 morphology , SMIg positive ) . Patients disease eligible current UKCCSG B cell NHL/ALL trial . 3 . Children Philadelphiapositive ALL ( ( 9 ; 22 ) BCR/ABL positive ) start induction therapy protocol transfer European Intergroup Protocol soon Philadelphia status know . Initially , eligible patient stratify three risk group base follow criterion : 1 . Standard risk : child &gt; 1 &lt; 10 year high white cell count start treatment &lt; 50x109/l , BCRABL , hypodiploidy ( ≥44 chromosome ) , MLL gene rearrangement . 2 . Intermediate risk : child ≥10 year old , diagnostic WBC ≥50x109/l ( ) BCRABL , hypodiploidy ( ≥44 chromosome ) , MLL gene rearrangement . 3 . High Risk : child , irrespective initial risk category , slow early response ( SER ) define see section 6 together BCRABL ( induction ) , hypodiploidy ( ≥44 chromosome ) , MLL gene rearrangement . These patient eligible MRD randomisation . Patients start treatment accord risk group follow : 1 . Standard risk , ( around 6065 % total ) : regimen A threedrug induction . 2 . Intermediate risk , ( around 20 30 % total ) : regimen B fourdrug induction . 3 . High risk ( around 1012 % total ) : These patient eligible MRD randomisation . They allocate regimen C four drug induction , augment BFM consolidation , Capizzi interim maintenance , two BFMstyle intensification period extend duration . Inclusion criterion entry randomisation : 1 . Standard Intermediate Risk define . 2 . Morphological Complete Remission ( BM1 Marrow ) Day 29 Induction . 3 . Availability MRD result Day 28 consolidation therapy . 4 . Informed consent obtain . 5 . Induction give protocol . Exclusion criterion entry MRD randomisation : 1 . High Risk define . These patient receive Regimen C. 2 . Day 28 nonremitters . These patient receive Regimen C BM2 go offprotocol BM3 ( see definition BM2 BM3 ) . 3 . MRD Indeterminate Group ( No result MRD positive &lt; 1 x 104 day 28 consolidation therapy ) continue previously assign therapy . 4 . Suboptimal induction therapy . The clinical significance day 28 MRD uncertain patient receive suboptimal induction therapy . Please discuss patient coordinator .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>